Intensive monitoring of pregabalin: Results from an observational, web-based, prospective cohort study in the netherlands using patients as a source of information

Drug Safety

Volumn 34, Issue 3, 2011, Pages 221-231

  Hrmark, Linda ^a,b   Van Puijenbroek, Eugne ^a   Straus, Sabine ^c,d   Van Grootheest, Kees ^a,b  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adverse reaction monitoring; Computers; Postmarketing surveillance; Pregabalin adverse reactions; Questionnaires

Indexed keywords

ANTIDIABETIC AGENT; PREGABALIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; APHASIA; ARTICLE; BACKACHE; BALANCE DISORDER; BLURRED VISION; CHILD; CONFUSION; CONSTIPATION; DIZZINESS; DRUG SURVEILLANCE PROGRAM; EDEMA; EPILEPSY; FATIGUE; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MEMORY DISORDER; NAUSEA; NEUROPATHIC PAIN; PARESTHESIA; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; CHILD; COHORT STUDIES; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; INTERNET; MALE; MIDDLE AGED; NETHERLANDS; NEURALGIA; PROSPECTIVE STUDIES; QUESTIONNAIRES; TIME FACTORS; YOUNG ADULT;

EID: 79951822353     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11585030-000000000-00000     Document Type: Article

References (25)

1. Jensen TS, Gottrup H, Sindrup SH, et al. The clinical picture of neuropathic pain. Eur J Pharmacol 2001 Oct 19; 429 (1-3): 1-11 (Pubitemid 33043977)
2. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006 Nov; 13(11): 1153-69 (Pubitemid 44581463)
3. Dieleman JP, Kerklaan J, Huygen FJ, et al. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008 Jul 31; 137 (3): 681-8
4. Collins SL, Moore RA, McQuay HJ, et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000 Dec; 20 (6): 449-58
5. Committee for Medicinal Products for Human Use (CHMP). EPAR: Lyrica® [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document- library/EPAR-Pro duct-Information/human/000546/WC500046602.pdf [Accessed 2010 Dec 1]
6. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for anti-epileptic drug discovery. Epilepsy Res 2007 Feb; 73 (2): 137-50 (Pubitemid 46329329)
7. Stricker BH, Psaty BM. Detection, verification, and quan- tification of adverse drug reactions. BMJ 2004 Jul 3; 329 (7456): 44-7 (Pubitemid 38870007)
8. Harmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008 Aug; 64 (8): 743-52
9. Raine JM. Risk management: a European regulatory view. In: Mann R, Andrews E, editors. Pharmacovigilance. Chichester: John Wiley & Sons Ltd, 2007: 553-8
10. Hazell L, Shakir SA. Under-reporting of adverse drug re- actions: a systematic review. Drug Saf 2006; 29 (5): 385-96
11. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan; 12 (1): 17-29 (Pubitemid 36192946)
12. Harmark L, Kabel JS, van Puijenbroek EP, et al. Web-based intensive monitoring, a new patient based tool for early signal detection [abstract no. 184]. Drug Saf 2006; 29 (10): 1005
13. Oosterhuis I, Harmark L, van Puijenbroek EP, et al. Lareb Intensive Monitoring: an interim analysis [abstract no. P091]. Drug Saf 2007; 30 (10): 960
14. van Grootheest AC, Harmark L, Oosterhuis I, et al. Lareb Intensive Monitoring, a web based system for monitoring ADRs in the postmarketing phase [abstract]. Pharmacoepidemiol Drug Saf 2007; 16: S252-3
15. Z-Index [online]. Available from URL: http://www.z-index.nl [Accessed 2010 Nov 15]
16. Shakir SAW. PEM in the UK. In: Mann R, Andrews E, editors. Pharmacovigilance. Chichester: John Wiley & Sons Ltd, 2007: 307-16
17. Coulter DM. The New Zealand Intensive Medicines Mon- itoring Programme. Pharmacoepidemiol Drug Saf 1998 Mar; 7 (2): 79-90 (Pubitemid 28252981)
18. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008 Jul; 31 (7): 1448-54
19. Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008 Jan; 23 (1): 18-28 (Pubitemid 350294866)
20. Food and Drug Administration. Statistical review and eval- uation: anti-epileptic drugs and suicidality [online]. Available from URL: http://www.fda.gov/downloads/Drugs/Drug Safety/ PostmarketDrugSafetyInformationforPatientsand Providers/UCM192556.pdf [Accessed 2010 Feb 22]
21. van Grootheest AC, van Puijenbroek EP, de Jong-van den Berg LT. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11 (3): 205-10 (Pubitemid 34537526)
22. Dutch Foundation for Pharmaceutical Statistics [online]. Available from URL: http://www.sfk.nl [Accessed 2010 Oct 27]
23. de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf 2008; 31 (6): 515-24 (Pubitemid 351693684)
24. van Grootheest K, de Graaf L, de Jong-van den Berg L. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26 (4): 211-7 (Pubitemid 36363604)
25. Centraal Bureau voor de Statistiek. Mediaproducten steeds meer via internet [media release]. 2008 Oct 28 [online]. Available from URL: http://www.cbs.nl/nl-NL/menu/themas/ vrije-tijd-cultuur/publicaties/artikelen/ archief/2008/2008-071-pb.htm [Accessed 2010 Oct 27]